FDA Highlights Potential Risks with Filled Intragastric Balloons by Apollo Endosurgery and ReShape Lifesciences

PUBLISHED: Jun 5, 2018
Relevant to: Ambulatory Care, Clinical Lab, Critical Access Hospitals, Hospitals, Medical Office

In collaboration with the manufacturers, the US Food and Drug Administration (FDA) has approved new labeling for the Orbera and ReShape balloon systems with more information about possible deaths associated with the use of these devices in the U.S. Please see the statements from each manufacturer (Apollo Endosurgery and ReShape Lifesciences) for additional details about the new labeling.

Intragastric balloon systems are weight-loss systems to treat obesity, which function by taking up space in a patient’s stomach. In 2015, the FDA approved two intragastric balloon systems in the U.S. The ReShape Integrated Dual Balloon System is manufactured by ReShape Medical Inc. and uses two balloons. The Orbera Intragastric Balloon System manufactured by Apollo Endo-Surgery uses one balloon. Both brands are liquid-filled balloon systems and are indicated for use in conjunction with diet and exercise.

The FDA recommends health care providers:

  • Instruct patients regarding symptoms of potentially life-threatening complications such as balloon deflation, gastrointestinal obstruction, ulceration, and gastric and esophageal perforation
  • Monitor patients closely during the entire term of treatment with liquid-filled intragastric balloon systems for potential complications, including acute pancreatitis and spontaneous hyperinflation as stated in the FDA's February 2017 letter to health care providers
  • Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.

Want to read the full alert and receive alert emails?

Browse Additional Alerts